Saturday, April 14, 2018

Goldman asks: 'Is curing patients a sustainable business model?'

Goldman asks: 'Is curing patients a sustainable business model?':

Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run.
"Is curing patients a sustainable business model?" analysts ask in an April 10 report entitled "The Genome Revolution."

No comments:

Post a Comment